The EGFR is frequently mutated in cancer, with exon 19 deletions and the exon 21 L858R point mutation commonly associated with NSCLC, while the EGFRvIII variant is a prevalent driver of glioblastomas (Orofiamma et al., 2022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.